HCV NS3/4A蛋白酶抑制剂Asunaprevir (BMS-650032)的发现及早期临床评价

{"title":"HCV NS3/4A蛋白酶抑制剂Asunaprevir (BMS-650032)的发现及早期临床评价","authors":"N. Meanwell, R. Rajamani, P. Scola, Li-Qiang Sun","doi":"10.1007/7355_2018_58","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12971,"journal":{"name":"HCV: The Journey from Discovery to a Cure","volume":"15 1","pages":"317 - 354"},"PeriodicalIF":0.0000,"publicationDate":"2018-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032)\",\"authors\":\"N. Meanwell, R. Rajamani, P. Scola, Li-Qiang Sun\",\"doi\":\"10.1007/7355_2018_58\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12971,\"journal\":{\"name\":\"HCV: The Journey from Discovery to a Cure\",\"volume\":\"15 1\",\"pages\":\"317 - 354\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HCV: The Journey from Discovery to a Cure\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/7355_2018_58\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HCV: The Journey from Discovery to a Cure","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/7355_2018_58","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}